SHANGHAI, May 24, 2019 /PRNewswire/ -- With fast advances
in the medical industry, on May 11,
2019, the third OrigiMed Summit for Cancer Discovery:
Immunotherapy and Targeted Therapy was successfully held in
Guangzhou. The summit was
sponsored by the Chinese Thoracic Oncology Group (CTONG) and the
International Cholangiocarcinoma Research Network (ICRN) and
organized by OrigiMed (Shanghai)
Ltd. At the summit, CTONG and OrigiMed jointly announced the
establishment of a new sharing clinical trial platform,
representing a new milestone in the strategic cooperation between
CTONG and OrigiMed.
Under the theme of "Deeper Cooperation, Greater Insight", the
summit brought together over 300 leading experts from home and
abroad to carry out in-depth discussions about the hottest topics
in immunotherapy and targeted therapy, promoting precision medicine
in China to the international
stage. Co-chaired by Professor Yilong
Wu, the chairman of CTONG, and Professor Shusen Zheng, vice president of Chinese Medical
Association, the specialists engaged in profound and comprehensive
discussions related to immunotherapy clinical practice, precision
targeted therapy, cholangiocarcinoma precision medicine, lung
cancer precision treatment, and contributed new thoughts and
insights for creating breakthroughs of cancer treatment in
China.
Many international experts in the precision medicine industry
attended the summit and shared their cutting-edge advancements in
the field. Among them were Professor Gordon
Freeman, a pioneer in immunotherapy from Dana-Farber
Cancer Institute, Harvard Medical
School; Prof. Carlos L. Arteaga,
expert in translational research in breast cancer and Director of
the Harold C. Simmons Comrehensive Cancer Center, UT Southwestern
Medical Center in Dallas;
Prof. Tony Mok, Lung Cancer expert
from the Department of Clinical Oncology at the Chinese University of Hong Kong; Prof. Milind Javle, gastrointestinal
oncologist from the MD Anderson Cancer Center; and Prof. Simon C.
Robson, an expert in Purinergic Signaling and Director of
Center for Inflammation Research at the Beth Israel Deaconess
Medical Center, Harvard Medical
School.
Prof. Yilong Wu, chairman of
CTONG, officially announced at the summit that a new sharing
platform for clinical trials would be established under the
strategic cooperation with OrigiMed. Once established, by
leveraging with OrigiMed's advantage in next generation sequencing
and the rich clinical experience of CTONG, the CTONG-OrigiMed
platform will focus on dealing with all sorts of complex clinical
cases and provide more clinical benefits to Chinese patients by the
new data sharing cooperation.
OrigiMed also revealed multiple new discoveries related to
Chinese cancer patients, including dataset of immunotherapy for the
Chinese tumor population, gene fusions distribution for Chinese
tumor patients, Dr. Groundhog Big Data Platform, and a NGS lung
cancer and breast cancer medical insurance upgrading project. These
new findings, coupled with clinical cases, could offer practical
applications to guide clinical treatment.
According to statistics from the National Cancer Center,
China has become the country with
the largest number of new cancer cases in the world. Each year,
there are more than 4.2 million newly diagnosed cancer patients and
the number of people dying from the disease has exceeded 2.8
million. Meanwhile, the precision medicine market in China is growing at an annual rate of 20%.
With the approval of all kinds of immunology and targeted drugs,
2018 was regarded as the first year of the rise of innovative drugs
in China. As new drugs, R&D
and entering the market are moving at a faster pace, genetic
testing for individualized treatment has also gained popularity.
Against such a backdrop, the third OrigiMed Summit for Cancer
Discovery has drawn particularly wide public attention.
"CTONG has paid close attention to clinical trials, in
particular precision medicine clinical trials. And OrigiMed has
been focusing on precise examination and specializing in gene
sequencing and immunotherapy," said
Prof. Yilong Wu, the chairman of
CTONG, lifetime director of Guangdong Provincial People's
Hospital. "Today, CTONG and
OrigiMed have joined hands to hold the third OrigiMed Summit for
Cancer Discovery and build the CTONG-OrigiMed new sharing clinical
trial platform. We welcome all the parties' participation to this
new, unique and sharing platform and create the future
together."
Dr. Kai Wang, CEO of
OrigiMed, expressed, "OrigiMed is
very honored to have the opportunity to cooperate with CTONG which
has made excellent contributions to the clinical research of lung
cancer in China in the past 12
years. Data has shown that there is an increasing number of
clinical cancer genes and biomarkers approved by guidebooks. With
more genes sequenced and the continuous progress made in precision
medicine, clinical guidance for gene classification and pan-cancer
precision medicine may be made available to achieve real
individualized medical care. It is our hope that the CTONG-OrigiMed
platform can unite Chinese and foreign experts to develop more
effective precision medicine clinical trials and solutions in
fighting against cancer."
The Summit was organized by OrigiMed (Shanghai) Ltd, a medical science and
technology transforming company focused on developing new
technologies and clinical applications for all types of cancer
patients. By carrying out more comprehensive and high-throughput
methods, leveraging whole genome bioinformatics analysis and
clinical annotation, OrigiMed identifies cancer specific molecular
markers and genomic features to guide targeted or immuno-therapy,
ultimately aiming to advance the evolution of cancer precision
medicine in China.
Based on the second-generation gene sequencing technique and in
line with different clinical stages, OrigiMed has developed gene
testing products such as tissue DNA, RNA, and plasma ctDNA
sequencing. The company's main service is the testing of several
hundred genes related to cancer, including all the types of solid
tumors. It has developed a first of its kind precision treatment
data sharing and follow-ups APP, called Dr. Groundhog Big Data
Platform, with a service network covering more than 400 hospitals
in five major areas across China.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ctong-origimed-new-clinical-trial-sharing-platform-launched-during-the-3rd-origimed-summit-for-cancer-discovery-300856435.html
SOURCE OrigiMed